Eohilia (Budesonide) Patent Expiration, LOE Window & CMS Spending

Eohilia (Budesonide) by Takeda: FDA Orange Book LOE 2039-01-10, 8 AB generics, $4.1M 2024 CMS Part D & Medicaid spend, and $1,875 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN213976 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-01-10
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$4.1M
2024 Medicare Part D Spend$1.6M
2024 Medicaid Spend$2.6M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,875 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.